IM/IV Injected SHELS for Uric Acid Decomposition

• Gout prevalence rate is increasing: 8 million people in U.S. alone increasing with a rate of 100,000 per year
• 1.5% develops refractory gout (120,000 in U.S.)
• Over 20 million people live with Chronic Kidney Disease (CKD) in the U.S.
• Some hospitalizations due to CKD require acute uric acid decomposition
• Uric acid decomposition used in the treatment of Tumor Lysis Syndrome (TLS)


• Uricase encapsulated within SHELS to decompose uric acid
• Shielded enzyme prevents immune reactions, avoids silent inactivation
• PEG-free formulation avoids reactions to PEG
• IV or IM administration for long term systemic depletion